Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 5/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | TFPI | P10646 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.40 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.39 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092691 | 0.98 | KRAS (0.42) | KRASRENTFPIKEAP1NPY4R | |
| SCHEMBL4255374 | 0.93 | REN (0.41) | KRASRENKEAP1KISS1RCTSB | |
| SCHEMBL4088444 | 0.90 | KISS1R (0.47) | KRASTFPIKISS1RVIPR1VIPR2 | |
| SCHEMBL4092747 | 0.89 | KRAS (0.42) | KRASKEAP1VIPR1VIPR2 | |
| SCHEMBL2367276 | 0.89 | NPY4R (0.43) | KRASRENKEAP1NPY4RVIPR1 | |
| SCHEMBL4099714 | 0.88 | REN (0.39) | KRASRENKEAP1KISS1RCTSB | |
| SCHEMBL4082466 | 0.87 | KRAS (0.43) | KRASKEAP1VIPR1VIPR2 | |
| SCHEMBL4082481 | 0.87 | OPRM1 (0.45) | RENTFPIKISS1RVIPR1CTSB | |
| SCHEMBL4088339 | 0.87 | KISS1R (0.49) | KRASTFPIKISS1RVIPR1VIPR2 | |
| SCHEMBL4255315 | 0.86 | KISS1R (0.48) | RENKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | KRAS 4279/4885REN 1728/4885TFPI 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.